english.prescrire.org > Spotlight > Archives : 2022 > Messenger RNA covid-19 vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°) during pregnancy

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

Messenger RNA covid-19 vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°) during pregnancy

in focusWhat main points should pregnant women be aware of in order to make informed decisions about covid-19 vaccination?

Key points

  • Pregnant women who become infected with Sars-CoV-2 are at higher risk of developing severe forms of covid-19 and potentially fatal complications, especially towards the end of pregnancy. These complications are more common in women with at least one risk factor, such as diabetes or hypertension.
     
  • In view of the consequences of covid-19 in pregnant women and the observed efficacy of the vaccines against the main variants prevalent in 2020 and 2021, the data available in early 2022 suggest that vaccination with tozinameran is useful for pregnant women, ideally between 10 weeks’ and 20 weeks’ gestation.
     
  • Vaccination helps, but does not replace, other preventive measures.
     

©Prescrire 1 June 2022

Source: "Messenger RNA covid-19 vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°) during pregnancy" Prescrire International 2022; 31 (238): 157-159. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

See also:

  COVID-19 
Follow Prescrire's
independent, evidence-based
analysis of the pandemic 
Free

Read more:

All the subjects in
Prescrire's Spotlight
Free >